Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
146
resultados
Última actualización
14/03/2026 [07:35:00]
Resultados 25 a 50 de 146
Resumen de: US20260053846A1
The disclosure provides polymeric compounds that inhibit binding of an amyloid-β-oligomer to cellular prior protein, methods for identifying such compounds, and their therapeutic use. In particular, the present disclosure provides a collection of anionic polymers and methods of using these compounds to treat amyloid-related disorders, e.g., Alzheimer's disease.
Resumen de: US20260055403A1
Methods for treating and/or preventing Alzheimer's disease via administration of thioredoxin-1 (Trx1) mRNA- or miR-551b miR-NA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1+ exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.
Resumen de: US20260053847A1
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheimer's disease (disease-modifying drug) contains hydrogen gas as an active ingredient.
Resumen de: US20260053747A1
The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell influx rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.
Resumen de: US20260053782A1
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of “wearing-off”, the treatment comprising administering more than N doses of levodopa per day to provide a total daily dose of X mg of levodopa and administering a single daily dose of Y mg of opicapone, wherein X is from 100 to 1000, N is from 2 to 10 and Y is from 25 to 50.
Resumen de: US20260053792A1
Compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof are provided. Specifically, a compound having a structure represented by general formula I, and a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable salt thereof, or a mixture thereof are provided. The compound promotes transcription factor EB (TFEB) nuclear translocation and lysosome generation, and can be used for preventing, treating, or assisting in treating various diseases related to lysosome dysfunction and biosynthesis insufficiency, especially neurodegenerative diseases caused by the accumulation of intracerebral pathological proteins (e.g., β-amyloid protein and α-synuclein), such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: EP4700016A2
It is an object of the present invention to provide a novel pharmaceutical agent or method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof, wherein the agent can be administered particularly to patients obtaining high therapeutic effects, among ALS patients who require treatments. According to the present invention, there is provided a pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing the disease progress thereof or treating symptoms caused by amyotrophic lateral sclerosis or suppressing the disease progress thereof, which comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, wherein the agent is administered by repeating a 14-day administration period and a 14-day drug holiday period, or by establishing an initial 14-day administration period and an initial 14-day drug holiday period and then repeating an administration period for 10 out of 14 days and a 14-day drug holiday period, and wherein a patient administered with the agent complies with specific criteria.
Resumen de: WO2026037826A1
Novel and useful compounds, such as 2,4-dihydropyrazolo3',4':4,5pyrano2,3-bpyridines, are disclosed herein. Such compounds may be employed in various treatments, alleviation, or prevention of a group of disorders, such as disorders associated with Tau (tubulin associated unit) protein aggregates, such as neurofibrillary tangles (NFTs), such as Alzheimer's disease (AD).
Resumen de: WO2026038861A1
The present invention relates to a novel chalcone derivative compound and a composition for the prevention or treatment of neurodegenerative diseases, comprising same as an active ingredient. The present invention can fundamentally eliminate the cause of neurotransmission dysfunction by simultaneously inhibiting the activities of two hyperactivated cholinesterases, unlike conventional symptomatic therapies that focus on the control of peripheral symptoms for various neurodegenerative diseases caused by a decrease in acetylcholine concentration, including Alzheimer's disease.
Resumen de: WO2026037392A1
The present invention provides a use of lactoferrin in combination with ergothioneine in the preparation of a drug for preventing and/or treating Alzheimer's disease. Compared with the use of lactoferrin or ergothioneine alone, in the present invention, the combined use of lactoferrin and ergothioneine at a specific ratio as an active pharmaceutical ingredient can reduce cell damage caused by Aβ25-35, reduce the expression of a p-Tau protein, lower the oxidative stress level and regulate apoptosis, alleviate memory impairment and cognitive dysfunction, and can reduce Aβ deposition in mouse plasma.
Resumen de: US20260048083A1
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Resumen de: US20260048058A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: US20260048090A1
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.
Resumen de: AU2024295008A1
The present invention recognizes that there is an unmet need for the treatment of mild cognitive impairment. A first aspect of the present invention generally relates to a method of treating, relieving, or alleviating mild cognitive impairment in a subject. A second aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease in a subject. A third aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease Psychosis in a subject. A fourth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease behaviors, aggression, agitation, anger, apathy, or a combination thereof, in a subject. A fifth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Early Onset Alzheimer's Disease in a subject.
Resumen de: AU2023455061A1
The present invention relates to a use of a novel compound for preventing, alleviating, or treating Parkinson's disease, the novel compound exhibiting an effect of inhibiting synuclein aggregation in a Parkinson's disease (PD) mouse model. As a result of histological analysis, it was confirmed that the loss of dopaminergic neurons was blocked by treatment with the novel compound. Therefore, the novel compound can be effectively utilized in the development of a therapeutic agent for Parkinson's disease.
Resumen de: EP4696713A1
A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.
Resumen de: AU2024250257A1
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Resumen de: EP4696712A1
An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of α-syn in the striatum and delaying the course of Parkinson's disease.
Resumen de: EP4696310A2
The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
Resumen de: AU2024343037A1
Provided is the new compositions and methods useful for the treatment, prevention, and potential cure of a genetic disease, such as familial Alzheimer's Disease, by disrupting the genomic sequence harboring one or more SNPs that are of high prevalence in a population but no relevance to the particular disease except for their genomic locations being in the same gene exon as a disease-relevant allele and upstream from such disease-relevant allele present in the genome of a treatment recipient.
Resumen de: WO2026036133A1
The invention provides binding agents targeted to the aggregated form of amyloid-beta (Aβ) peptide, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and pharmaceutical compositions thereof. The invention also provides methods for treating or preventing a disease, disorder, or condition, in particular, Alzheimer's disease, in a mammal, by administering the binding agents or compositions thereof. The invention further provides methods for inducing clearance of an aggregated form of amyloid-beta (Aβ) peptide in a mammal, comprising administering the inventive binding agents and pharmaceutical compositions described herein.
Resumen de: WO2026032004A1
The present invention relates to a method for treating Parkinsonism or Parkinson's disease, and a pharmaceutical composition, and specifically relates to a pharmaceutical composition, the use and a method of a peripheral μ-opioid receptor antagonist for treating Parkinsonism or Parkinson's disease. The pharmaceutical composition, use and method can significantly ameliorate symptoms of Parkinsonism or Parkinson's disease, including constipation, particularly constipation that is unresponsive or refractory to treatment with general-purpose constipation drugs.
Resumen de: WO2026032421A1
Provided herein are anti-overdosing compositions and uses thereof. Specifically, provided herein are anti-overdosing pharmaceutical compositions comprising a mitochondrial uncoupler and a GLP-1R agonist and uses thereof as well as methods for preventing overdosing of the uncoupler. Such pharmaceutical compositions can be useful for treating diseases, such as but not limited to NASH, overweight, obesity, medical complications related to overweight or obesity, type 2 diabetes (T2D), and Alzheimer's disease and related dementias (AD/ADRD).
Resumen de: US20260043791A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Nº publicación: WO2026035942A1 12/02/2026
Solicitante:
BOARD OF REGENTS OF THE UNIV OF NEBRASKA [US]
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Resumen de: WO2026035942A1
The present invention provides novel compositions and methods for treating diseases and conditions associated with amyloid beta in a subject, said method comprising administering to the subject (i) an anti-amyloid beta antibody or an antigen binding fragment thereof and (ii) a regulatory T cell (Treg) inducing or activating agent.
BOPI
Sede Electrónica
